Thomas Lodise, Pharm.D., Ph.D.



  • Ph.D. in Epidemiology, University at Albany
  • Pharm.D., Temple University School of Pharmacy

Courses Taught at ACPHS

  • Pharmacotherapy III (Infectious Diseases Module) 
  • Drug Information (study design and statistics)

Research Interests

Integrating his dual interests in research and patient care, Dr. Lodise’s current research focuses on the epidemiology and outcomes of bacterial infections, and his work explores the antibiotic exposure-response relationship among patients. His specific objectives are threefold: develop patient care strategies and antibiotic regimens that improve outcomes, reduce the likelihood of toxicity and minimize the emergence of antibiotic resistance. 

Dr. Lodise is currently implementing epidemiologic and outcomes research proposals at both the Albany Medical Center and Stratton VA Medical Center. He also collaborates extensively with the Ordway Research Institute in Albany. He has received funding from both the pharmaceutical industry and competitive grant sources for many of his proposals. To date, he has published over 30 peer-reviewed articles in reputable scientific journals, including Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy, Chest and Journal of Antimicrobial Chemotherapy.


Hospital Affiliation

  • Dr. Lodise is a Clinical Pharmacist at the Stratton VA Medical Center in Albany, NY.

Selected Publications

Lodise TP, Miller CD, Evans A, Graves J, Graffunder E, Helmecke M, Stellrecht K. Predictors of High Vancomycin MIC Values among Patients with MRSA Bacteraemia.Journal of Antimicrobial Chemotherapy 2008 Aug 11. 

Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K. Relationship between Vancomycin MIC and Failure among Patients with MRSA Bacteremia Treated with Vancomycin. Antimicrobial Agents and Chemotherapy 2008 Sep;52(9):3315-20. Epub 2008 Jun 30. 

Patel N, McNutt LA, Lodise TP. Predictors of piperacillin-resistant Pseudomonas aeruginosa among patients with respiratory tract infections: the predictive value of varying exposure definitions and the risk of multiple prior antibiotic exposures.Antimicrobial Agents and Chemotherapy 2008 Aug;52(8):2933-6. Epub 2008 Jun 2.

Lodise TP, Gotfried M, Barriere S, Drusano GL. Telavancin Penetration into Human Epithelial Lining Fluid as Determined by Population Pharmacokinetic Modeling and Monte Carlo Simulation. Antimicrobial Agents and Chemotherapy 2008 Jul;52(7):2300-4. Epub 2008 Apr 21. 

Mohr JF, Peymann PJ, Troxell E, Lodise TP, Ostrosky-Zeichner L. Risk Factors for Hyperglycemia in Hospitalized Adults Receiving Gatifloxacin: A Retrospective, Nested Case- Controlled Analysis. Clinical Therapeutics. 2008 Jan;30(1):152-7. 

Lodise TP, Lomaestro BM, Graves J, Drusano GL. Larger Vancomycin Doses are Associated with an Increased Incidence of Nephrotoxicity. Antimicrobial Agents and Chemotherapy 2008 Apr;52(4); 1330-6. Epub 2008 Jan 28. 

Lodise TP, Patel N, Renaud-Mutart A, Gorodecky E, Fritsche TR, Jones RN. Pharmacokinetic and Pharmacodynamic Profile of Ceftobiprole. Diagnostic Microbiology and Infectious Diseases 2008 May;61(1):96-102. Epub 2008 Apr 2. 

Lodise TP, Neuhauser M. Community-Associated Methicillin-Resistant Staphylococcus aureus. In: Dunsworth T, Richardson M, Chant C, Cheng JWM, Chessman KH, Hume AL, et al, eds. Pharmacotherapy Self-Assessment Program, Sixth Edition. Infectious Diseases. Lenexa, Kan.: American College of Clinical Pharmacy, 2008: 37- 54. 

Lodise TP, Lomaestro BM, Drusano GL. Practical Application of Pharmacodynamic Principles to Optimize Therapy and Treat Resistant Organisms: A Focus on Beta-Lactam Antibiotics. In Owens RC and Lautenbach E. Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures. Informa Healthcare USA, Inc, 2008: 317- 335. 

McKinnon PS, Lodise TP. Outcomes and Cost Considerations with MRSA Infections. In Weigelt. MRSA. Informa Healthcare USA, Inc, 2008: 189-211. 

Lodise TP, McKinnon PS. Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes. Pharmacotherapy. 2007 Jul;27(7):1001-12.

Lodise TP, Kinzig-Schippers M, Drusano GL, Loos U, Vogel F, Bulitta J, Hinder M, Sörgel F. Use of Population Pharmacokinetic Modeling and Monte Carlo Simulation to Describe the Pharmacodynamic Profile of Cefditoren in Plasma and Epithelial Lining Fluid. Antimicrobial Agents and Chemotherapy 2008 Jun;52(6):1945-51. Epub 2007 May 7. 

Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP. Comparison of ß-lactam and Macrolide Combination Therapy vs. Fluoroquinolone Monotherapy in Hospitalized Veteran Affairs’ Patients with Community-Acquired Pneumonia. Antimicrobial Agents and Chemotherapy. 2007 Nov;51(11):3977-82. Epub 2007 Aug 20. 

Bhat SV, Peleg AY, Lodise TP, Shutt KA, Capitano B, Potoski BA, Paterson DL. Failure of current cefepime breakpoints to predict clinical outcomes from Gram negative bacteremia. Antimicrobial Agents and Chemotherapy 2007 Dec;51(12):4390-5. Epub 2007 Oct 15.

Lodise TP, Graves J, Miller C, Mohr JF, Lomaestro BM, Smith RP. Incidence of Hypo- and Hyperglycemia Among Elderly, Hospitalized Patients: A Comparison between Gatifloxacin and Levofloxacin. Pharmacotherapy 2007 Nov;27(11):1498-505.

Miller CD, El-Kholi R, Faragon J, Lodise TP. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy. Pharmacotherapy. 2007 Oct;27(10):1379-86.

Lodise TP, Nau R, Kinzig M, Drusano GL, Jones RN, Sörgel F. Pharmacodynamics of Ceftazidime and Meropenem in Cerebrospinal Fluid: Results of Population Pharmacokinetic Modeling and Monte Carlo Simulation. Journal Antimicrobial Chemotherapy. 2007 Nov;60(5):1038-44. Epub 2007 Sep 4. 

McGregor JC, Rich SA, Harris AD, Perencevich EN, Osih R, Lodise Jr. TP, Miller RR, Furuno JP. A Systematic Review of the Methods Used to Assess the Association Between Appropriate Antibiotic Therapy and Mortality in Bacteremic Patients. Clinical Infectious Diseases. 2007 Aug 1;45(3):329-37. 

Lodise TP, McKinnon PS, Levine DP, Rybak MJ. Impact of Empirical Therapy Selection on Outcomes of Intravenous Drug Users with Methicillin Susceptible Staphylococcus aureus Infective Endocarditis. Antimicrobial Agents and Chemotherapy. 2007 Oct;51(10):3731-3. Epub 2007 Jul 30. 

Lodise TP, Patel N, Graves J, Kwa A, Furuno JP, Graffunder E, Lomaestro BM, McGregor JC. Predictors of 30-Day Mortality among Patients with Pseudomonas aeruginosa Bloodstream Infections: The Impact of Delayed Appropriate Antibiotic Selection. Antimicrobial Agents and Chemotherapy. 2007 Oct;51(10):3510-5. Epub 2007 Jul 23.

Lodise TP, Miller CD, Patel N, Graves J, McNutt LA. Identification of Patients with Pseudomonas aeruginosa Respiratory Tract Infections at Greatest Risk for Carbapenem Resistance. Infection Control and Hospital Epidemiology. 2007 Aug;28(8):959-65. Epub 2007 Jun 22.

Lodise TP, Nau R, Kinzig M, Jones RN, Sörgel F. Comparison of the Probability of Target Attainment Between Ceftriaxone and Cefepime in the Cerebrospinal Fluid and Plasma against Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease. 2007 Aug;58(4):445-52. Epub 2007 May 23.

Laplante KL, Rybak MJ, Tsuji B, Lodise TP, Kaatz GW. Fluoroquinolone Resistance in Streptococcus pneumoniae: Area Under the Concentration-Time Curve/MIC Ratio and Resistance Development with Gatifloxacin, Gemifloxacin, Levofloxacin, and Moxifloxacin. Antimicrobial Agents Chemotherapy. 2007 Apr; 51(4):1315-20.

Lodise Jr. TP, Pypstra R, Kahn JB, Murty BP, Kimko HC, Bush K, Noel G, Drusano GL. Probability of Target Attainment for Ceftobiprole as Derived from a Population Pharmacokinetic Analysis of 150 Subjects. Antimicrobial Agents and Chemotherapy. 2007 Jul;51(7):2378-87. Epub 2007 Mar 26. 

Lodise TP, Miller CD, Graves J, Furuno JP, McGregor JC, Lomaestro BM, Graffunder E, McNutt LA. Clinical Prediction Tool to Identify Patients with Pseudomonas aeruginosa Respiratory Tract Infections at Greatest Risk for Multi-Drug Resistance. Antimicrobial Agents and Chemotherapy. 2007 Feb; 51(2):417-22.

Lodise TP, Lomaestro BM, Drusano GL. Piperacillin/Tazobactam for Pseudomonas aeruginosa Infections: Clinical Implications of an Extended Infusion Dosing Strategy. Clinical Infectious Diseases. 2007 Feb 1; 44(3):357-63.

Department of Pharmacy Practice